POSEIDON Delivers For AstraZeneca's Imfinzi, But More Clarity Is Needed

 
• By Jessica Merrill

Imfinzi and tremelimumab plus chemotherapy improved PFS in first-line NSCLC, but overall survival is continuing to be assessed, and AstraZeneca did not clarify how the triple combination compared to Imfinzi alone with chemotherapy.

SC1910_Cyclists_170970920_1200.jpg
AstraZeneca hopes to catch up to the leaders in metastatic NSCLC • Source: Shutterstock

More from Anticancer

More from Therapy Areas